Vector BioMed

Executive Summary

Vector BioMed is a private, US-based public benefit corporation founded in 2016 that specializes in the design and manufacturing of lentiviral vectors for gene therapies and vaccines. The company provides essential viral vector capabilities to accelerate the translation of groundbreaking science into accessible treatments, with a focus on global reach and affordability. Its services span from research-grade to GMP manufacturing, aiming to reduce barriers for therapy developers. As a pre-clinical stage company, Vector BioMed plays a critical role in the gene therapy supply chain, enabling clients to move from discovery to clinical trials by offering scalable, high-quality vector production. The company's business model is centered on de-risking manufacturing for its partners, leveraging its expertise in lentiviral vector technology to support a range of therapeutic modalities, including CAR-T, gene editing, and vaccine development. Despite being early-stage and privately held, Vector BioMed has established a presence in the gene therapy ecosystem and is positioned to benefit from the growing demand for viral vector manufacturing capacity, particularly as more gene therapies advance in the clinic.

Upcoming Catalysts (preview)

• Q3 2026GMP Manufacturing Facility Qualification or Expansion70% success
• Q4 2026Strategic Partnership with a Major Gene Therapy Developer60% success
• H1 2027Series A or B Funding Round to Scale Operations80% success